{"id":42802,"date":"2023-12-18T05:46:14","date_gmt":"2023-12-18T04:46:14","guid":{"rendered":"http:\/\/www.infokuryr.cz\/n\/?p=42802"},"modified":"2023-12-18T05:46:14","modified_gmt":"2023-12-18T04:46:14","slug":"japonsko-uvadi-na-trh-samoreplikujici-se-mrna-vakciny-biozbran-nove-generace","status":"publish","type":"post","link":"https:\/\/www.infokuryr.cz\/n\/2023\/12\/18\/japonsko-uvadi-na-trh-samoreplikujici-se-mrna-vakciny-biozbran-nove-generace\/","title":{"rendered":"Japonsko uv\u00e1d\u00ed na trh samoreplikuj\u00edc\u00ed se mRNA \u201evakc\u00edny\u201c \u2013 biozbra\u0148 nov\u00e9 generace"},"content":{"rendered":"
<\/div>\n

P\u0159ed dv\u011bma t\u00fddny se Japonsko stalo prvn\u00ed zem\u00ed na sv\u011bt\u011b, kter\u00e1 schv\u00e1lila novou samoreplikuj\u00edc\u00ed se mRNA vakc\u00ednu (\u201e sa-mRNA\u201c). Po jej\u00edm schv\u00e1len\u00ed se nyn\u00ed v\u00fdvoj\u00e1\u0159i sna\u017e\u00ed io autorizaci v Evrop\u011b. Rozhodnut\u00ed regul\u00e1tora se o\u010dek\u00e1v\u00e1 p\u0159\u00ed\u0161t\u00ed rok.<\/span><\/p>\n

Samoreplikuj\u00edc\u00ed se RNA (\u201cse-mRNA\u201d) je vytvo\u0159ena tak, aby po dod\u00e1n\u00ed do bun\u011bk vytvo\u0159ila v\u00edce kopi\u00ed sebe sama. K\u00f3duje tedy dv\u011b v\u011bci – po\u017eadovan\u00fd antigen, nap\u0159\u00edklad covidov\u00fd hrotov\u00fd protein, i proteiny, kter\u00e9 umo\u017e\u0148uj\u00ed replikaci samotn\u00e9 vakc\u00ednov\u00e9 RNA.<\/span><\/p>\n

Spole\u010dnost s n\u00e1zvem\u00a0<\/span>Meiji Seika Pharma<\/span><\/em>\u00a0zve\u0159ejnila prohl\u00e1\u0161en\u00ed dne 28. listopadu 2023, ve kter\u00e9m ozn\u00e1mila, \u017ee japonsk\u00e9 ministerstvo zdravotnictv\u00ed schv\u00e1lilo v\u00fdrobu a prodej je Kostaive se-mRNA covidov\u00e9 vakc\u00edny, tak\u00e9 zn\u00e1m\u00e9 jako ARCT-154 (nebo ve Vietnamu VBC-COV19-154).<\/span><\/p>\n

Spole\u010dnost\u00a0<\/span>Meiji Seika Pharma<\/span><\/em>\u00a0uzav\u0159ela exkluzivn\u00ed partnerstv\u00ed pro distribuci sv\u00e9 vakc\u00edny s farmaceutickou firmou CSL Seqirus, jedn\u00edm z nejv\u011bt\u0161\u00edch v\u00fdrobc\u016f vakc\u00edn proti ch\u0159ipce na sv\u011bt\u011b.<\/span><\/p>\n

Schv\u00e1len\u00ed bylo ud\u011bleno navzdory st\u00e1le prob\u00edhaj\u00edc\u00ed 3. f\u00e1zi klinick\u00fdch zkou\u0161ek, kter\u00e9 financuje japonsk\u00e1 vl\u00e1da a testov\u00e1n\u00ed produktu jen na 838 lidech, kte\u0159\u00ed d\u0159\u00edve obdr\u017eeli t\u0159i d\u00e1vky vakc\u00edny.<\/span><\/p>\n

Krom\u011b toho, jak uv\u00e1d\u00ed port\u00e1l\u00a0<\/span>ZeroHedge<\/span><\/a>, v\u00fdsledky studie nebyly zve\u0159ejn\u011bny. Podle zpr\u00e1vy o 3. f\u00e1zi klinick\u00fdch zkou\u0161ek je rukopis ve st\u00e1diu \u201ep\u0159\u00edpravy\u201c. Vakc\u00edna vy\u017eaduje pod\u00e1n\u00ed 2 d\u00e1vek, p\u0159i\u010dem\u017e druh\u00e1 d\u00e1vka se pod\u00e1 28 dn\u00ed po prvn\u00ed. Pro dosp\u011bl\u00e9 ve v\u011bku 18 let a star\u0161\u00ed se pod\u00e1v\u00e1 tak\u00e9 t\u0159et\u00ed posilovac\u00ed d\u00e1vka.<\/span><\/p>\n

Vakc\u00edna Kostaive se-mRNA byla vyvinuta spole\u010dnost\u00ed Arcturus Therapeutics, kter\u00e1 podle Crunchbase je financov\u00e1na 3 investory \u2013 Nadac\u00ed cystick\u00e9 fibr\u00f3zy, japonskou vl\u00e1dou a \u00da\u0159adem pro pokro\u010dil\u00fd biomedic\u00ednsk\u00fd v\u00fdzkum a v\u00fdvoj (BARDA).<\/span><\/p>\n

BARDA je pobo\u010dkou Ministerstva zdravotnictv\u00ed a soci\u00e1ln\u00edch slu\u017eeb USA, kter\u00e1 zodpov\u011bdn\u00e1 za v\u00fdvoj l\u00e9ka\u0159sk\u00fdch protiopat\u0159en\u00ed proti bioterorismu, CBRN hrozb\u00e1m, pandemick\u00e9 ch\u0159ipce a nov\u00fdm chorob\u00e1m.<\/span><\/p>\n

Vakc\u00edna Kostaive krom\u011b koronavirov\u00e9ho hrotov\u00e9ho proteinu k\u00f3duje dal\u0161\u00ed \u010dty\u0159i proteiny, co\u017e umo\u017e\u0148uje amplifikaci p\u016fvodn\u00edho vl\u00e1kna RNA, jakmile se obsah vakc\u00edny dostane dovnit\u0159 bu\u0148ky. Replika\u010dn\u00ed mechanismus a extra proteiny poch\u00e1zej\u00ed z viru zn\u00e1m\u00e9ho jako \u201evirus venezuelsk\u00e9 ko\u0148sk\u00e9 encefalitidy\u201c, kter\u00fd je patogenem p\u0159en\u00e1\u0161en\u00fdm kom\u00e1ry.<\/span><\/p>\n

Jako d\u016fvod v\u00fdvoje tohoto nov\u00e9ho samoreplika\u010dn\u00edho typu vakc\u00edny uv\u00e1d\u00ed \u010dl\u00e1nek zve\u0159ejn\u011bn\u00fd v \u010dasopise Nature: \u201eproto\u017ee se m\u016f\u017ee pou\u017e\u00edt v ni\u017e\u0161\u00ed d\u00e1vce, tak\u017ee m\u016f\u017ee m\u00edt m\u00e9n\u011b vedlej\u0161\u00edch \u00fa\u010dink\u016f ne\u017e jin\u00e9 terapie zalo\u017een\u00e9 na\u00a0<\/span>mRNA technologii<\/span><\/a>\u201c.<\/span><\/p>\n

Dal\u0161\u00edm d\u016fvodem, jak poznamenal Portland Press, je sn\u00ed\u017een\u00ed n\u00e1klad\u016f na vakc\u00edny.<\/span><\/p>\n

Rozd\u00edl mezi covidovou mRNA vakc\u00ednou a covidovou se-mRNA vakc\u00ednou je v tom, \u017ee p\u0159i prvn\u00ed vakc\u00edn\u011b bun\u011b\u010dn\u00fd mechanismus produkuje hrotov\u00fd protein tak dlouho, dokud tyto instrukce p\u0159etrv\u00e1vaj\u00ed (tedy dokud mRNA nen\u00ed rozlo\u017eena bun\u011b\u010dn\u00fdmi enzymy), dokud vakc\u00edna sa-mRNA jde o krok d\u00e1le.<\/span><\/p>\n

\u201eIntegruje geny pot\u0159ebn\u00e9 pro replikaci a synt\u00e9zu RNA k\u00f3duj\u00edc\u00ed hrotov\u00fd protein, \u010d\u00edm\u017e efektivn\u011b vytv\u00e1\u0159\u00ed biologick\u00fd tiska\u0159sk\u00fd lis pro v\u00fdrobu vakc\u00edny uvnit\u0159 bun\u011bk,\u201c<\/span><\/em>\u00a0dod\u00e1v\u00e1 \u010dasopis Nature.<\/span><\/p>\n

Ve\u00a0<\/span>video<\/span><\/a>\u00a0n\u00ed\u017ee (v angli\u010dtin\u011b) Roman Balmakov vysv\u011btluje v\u00edce:<\/span><\/p>\n

 <\/p>\n

\r\n\t